Organogenesis (ORGO) Competitors $4.05 +0.03 (+0.75%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ORGO vs. FLXN, NLTX, ARDX, MDXG, IART, AMPH, MIRM, CNTA, APGE, and EVOShould you be buying Organogenesis stock or one of its competitors? The main competitors of Organogenesis include Flexion Therapeutics (FLXN), Neoleukin Therapeutics (NLTX), Ardelyx (ARDX), MiMedx Group (MDXG), Integra LifeSciences (IART), Amphastar Pharmaceuticals (AMPH), Mirum Pharmaceuticals (MIRM), Centessa Pharmaceuticals (CNTA), Apogee Therapeutics (APGE), and Evotec (EVO). These companies are all part of the "medical" sector. Organogenesis vs. Flexion Therapeutics Neoleukin Therapeutics Ardelyx MiMedx Group Integra LifeSciences Amphastar Pharmaceuticals Mirum Pharmaceuticals Centessa Pharmaceuticals Apogee Therapeutics Evotec Organogenesis (NASDAQ:ORGO) and Flexion Therapeutics (NASDAQ:FLXN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, community ranking, media sentiment and analyst recommendations. Do insiders and institutionals have more ownership in ORGO or FLXN? 49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 90.0% of Flexion Therapeutics shares are owned by institutional investors. 36.9% of Organogenesis shares are owned by company insiders. Comparatively, 9.1% of Flexion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts recommend ORGO or FLXN? Organogenesis currently has a consensus target price of $5.33, suggesting a potential upside of 31.69%. Given Organogenesis' stronger consensus rating and higher possible upside, equities analysts clearly believe Organogenesis is more favorable than Flexion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organogenesis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Flexion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer ORGO or FLXN? Flexion Therapeutics received 475 more outperform votes than Organogenesis when rated by MarketBeat users. However, 66.44% of users gave Organogenesis an outperform vote while only 63.34% of users gave Flexion Therapeutics an outperform vote. CompanyUnderperformOutperformOrganogenesisOutperform Votes9766.44% Underperform Votes4933.56% Flexion TherapeuticsOutperform Votes57263.34% Underperform Votes33136.66% Is ORGO or FLXN more profitable? Organogenesis has a net margin of -1.62% compared to Flexion Therapeutics' net margin of -100.32%. Flexion Therapeutics' return on equity of 0.00% beat Organogenesis' return on equity.Company Net Margins Return on Equity Return on Assets Organogenesis-1.62% -2.69% -1.63% Flexion Therapeutics -100.32%N/A -44.26% Which has preferable earnings & valuation, ORGO or FLXN? Organogenesis has higher revenue and earnings than Flexion Therapeutics. Organogenesis is trading at a lower price-to-earnings ratio than Flexion Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganogenesis$455.04M1.18$4.95M-$0.06-67.50Flexion Therapeutics$85.55M5.36-$113.71M-$2.01-4.54 Which has more risk and volatility, ORGO or FLXN? Organogenesis has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, Flexion Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Does the media favor ORGO or FLXN? In the previous week, Organogenesis had 6 more articles in the media than Flexion Therapeutics. MarketBeat recorded 6 mentions for Organogenesis and 0 mentions for Flexion Therapeutics. Organogenesis' average media sentiment score of 0.52 beat Flexion Therapeutics' score of 0.00 indicating that Organogenesis is being referred to more favorably in the media. Company Overall Sentiment Organogenesis Positive Flexion Therapeutics Neutral SummaryOrganogenesis beats Flexion Therapeutics on 13 of the 18 factors compared between the two stocks. Ad Genesis Gold GroupTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov Get Organogenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGO vs. The Competition Export to ExcelMetricOrganogenesisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$536.94M$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E Ratio-67.5011.10105.1417.83Price / Sales1.18362.031,233.15158.41Price / Cash18.9752.5940.4136.29Price / Book1.9310.377.096.50Net Income$4.95M$153.60M$119.65M$226.22M7 Day Performance4.92%4.60%2.25%4.03%1 Month Performance40.14%-6.29%-2.33%4.92%1 Year Performance56.37%33.41%33.98%29.30% Organogenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGOOrganogenesis4.1203 of 5 stars$4.05+0.7%$5.33+31.7%+56.4%$536.94M$455.04M-67.50950FLXNFlexion TherapeuticsN/A$9.12flatN/AN/A$458.93M$85.55M-4.54257NLTXNeoleukin TherapeuticsN/A$15.59+1.7%N/A+46.3%$146.52MN/A-5.0190High Trading VolumeARDXArdelyx4.016 of 5 stars$5.14+4.5%$10.42+102.5%+23.2%$1.17B$251.85M-17.15267Insider TradeMDXGMiMedx Group3.1211 of 5 stars$9.22+1.8%$12.00+30.2%+21.5%$1.35B$321.48M16.76895IARTIntegra LifeSciences2.8749 of 5 stars$23.00+0.3%$24.00+4.3%-39.8%$1.77B$1.54B-255.533,946Positive NewsHigh Trading VolumeAMPHAmphastar Pharmaceuticals4.8709 of 5 stars$44.47+0.9%$63.00+41.7%-18.9%$2.12B$723.55M14.821,761Analyst ForecastPositive NewsGap UpMIRMMirum Pharmaceuticals4.3331 of 5 stars$43.48-0.5%$57.73+32.8%+39.8%$2.09B$186.37M-21.52140CNTACentessa Pharmaceuticals4.0521 of 5 stars$18.19+8.7%$25.83+42.0%+160.6%$2.06B$6.85M-11.8972Insider TradeAnalyst RevisionNews CoverageAPGEApogee Therapeutics2.4626 of 5 stars$43.28-3.9%$78.50+81.4%+152.2%$1.95BN/A-17.8891EVOEvotec2.7256 of 5 stars$5.35+0.9%$5.93+10.9%-56.6%$1.90B$845.74M0.005,061Gap Down Related Companies and Tools Related Companies Flexion Therapeutics Alternatives Neoleukin Therapeutics Alternatives Ardelyx Alternatives MiMedx Group Alternatives Integra LifeSciences Alternatives Amphastar Pharmaceuticals Alternatives Mirum Pharmaceuticals Alternatives Centessa Pharmaceuticals Alternatives Apogee Therapeutics Alternatives Evotec Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ORGO) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organogenesis Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organogenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORGO Stock Alerts